Article
ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy.
Pharmacogenetics and genomics - 1 Nov 2013
Rumiato Enrica, Cavallin Francesco, Boldrin Elisa, Cagol Matteo, Alfieri Rita, Basso Daniela, Castoro Carlo, Ancona Ermanno, Amadori Alberto, Ruol Alberto, Saggioro Daniela
Abstract excerpt
OBJECTIVE: At present, no consensus exists on the beneficial effect of preoperative cisplatin/5-fluorouracil (5-FU)-based chemotherapy versus primary surgery in the management of patients with esophageal cancer. The aim of this study was to evaluate the impact of some relevant genetic polymorphisms, within drug-related and DNA repair genes, on the clinical outcome of esophageal cancer patients subjected to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
